Tag: prostate cancer

The rate of newly diagnosed patients with Gleason 3+3 (Grade Group 1) prostate cancer who choose go on Active Surveillance instead of immediate treatment has increased significantly in the last decade. There’s considerable expert opinion that... keep reading

The FDA-approved PCA3 urine test (Progensa) for detecting a biomarker that is overexpressed in prostate cancer (PCa) was acknowledged by the American Urological Association as far back as 2013 as a useful adjunct – along with other PSA derivatives – for determining if a biopsy or repeat biopsy was needed. keep reading

Despite cancer warnings, let’s face it. Untold millions of meat-lovers—and the restaurants that cater to them—continue to grill meat over high heat or open flames. As we wrote in the original blog, this causes the formation of carcinogens called heterocyclic aromatic amines (HAAs). keep reading

It’s been over 6 years since I posted the blog below. During the intervening years, my colleagues in prostate imaging continued an ongoing discussion on the pros and cons of an endorectal (in the rectum) imaging antenna during multiparametric MRI of the prostate... keep reading

In January, 2018 we posted a blog on several spices that have an observed anti-cancer affect when laboratory-tested on cancer cells or animals. This update focuses on turmeric and a compound derived from it, curcumin. Curcumin has been shown to... keep reading

Here is more recent news about a genomic analysis of prostate tissue from men in the study described below who developed prostate cancer. The research team, including some authors from the original study, tested for trends in gene expression according to the level of ejaculation frequency... keep reading

Here it is, December of 2020. It’s been the Year of the Pandemic, and possibly also the Year of Increased Drinking. A September 29 ABC News story reported a sharp increase in U.S. alcohol consumption—especially among women—perhaps as a way to cope with feelings of isolation, depression and anxiety. keep reading

Here is fantastic news for men who undergo an initial treatment for localized prostate cancer! In November, 2020 the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RV001, an investigational vaccine against prostate cancer recurrence after primary treatment. RV001 is manufactured by a Swedish pharmaceutical company called RhoVac. Let’s look at the keep reading

One of the most respected prostate cancer research facilities is the National Cancer Institute: The National Cancer Institute (NCI) is the federal government’s principal agency for cancer research and training. Established under the National Cancer Institute Act of 1937, NCI is part of the National Institutes of Health (NIH), one of 11 agencies that make keep reading

NOTE: The following is an update to a blog I posted in early 2020. Metformin red flag, December 2019 I have occasionally reported on studies that link a possible preventive effect against prostate cancer (PCa) with the common diabetes drug, metformin. In February 2020 I notified readers that the FDA had issued a Dec. 2019 keep reading